AT300610T - Libraries of polyclonal antibodies - Google Patents

Libraries of polyclonal antibodies

Info

Publication number
AT300610T
AT300610T AT02000290T AT02000290T AT300610T AT 300610 T AT300610 T AT 300610T AT 02000290 T AT02000290 T AT 02000290T AT 02000290 T AT02000290 T AT 02000290T AT 300610 T AT300610 T AT 300610T
Authority
AT
Austria
Prior art keywords
libraries
polyclonal antibodies
polyclonal
antibodies
Prior art date
Application number
AT02000290T
Other languages
German (de)
Inventor
Jacqueline Sharon
Original Assignee
Univ Boston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US18936094A priority Critical
Application filed by Univ Boston filed Critical Univ Boston
Publication of AT300610T publication Critical patent/AT300610T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES, IN SILICO LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/02Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1037Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
AT02000290T 1994-01-31 1995-01-27 Libraries of polyclonal antibodies AT300610T (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US18936094A true 1994-01-31 1994-01-31

Publications (1)

Publication Number Publication Date
AT300610T true AT300610T (en) 2005-08-15

Family

ID=22696993

Family Applications (2)

Application Number Title Priority Date Filing Date
AT95909384T AT243745T (en) 1994-01-31 1995-01-27 Libraries of polyclonal antibodies
AT02000290T AT300610T (en) 1994-01-31 1995-01-27 Libraries of polyclonal antibodies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT95909384T AT243745T (en) 1994-01-31 1995-01-27 Libraries of polyclonal antibodies

Country Status (9)

Country Link
US (2) US5789208A (en)
EP (2) EP1231268B1 (en)
AT (2) AT243745T (en)
AU (1) AU1736495A (en)
DE (4) DE69531148D1 (en)
DK (2) DK1231268T3 (en)
ES (2) ES2201097T3 (en)
PT (2) PT1231268E (en)
WO (1) WO1995020401A1 (en)

Families Citing this family (469)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866344A (en) * 1991-11-15 1999-02-02 Board Of Regents, The University Of Texas System Antibody selection methods using cell surface expressed libraries
US20030036092A1 (en) * 1991-11-15 2003-02-20 Board Of Regents, The University Of Texas System Directed evolution of enzymes and antibodies
US20060078561A1 (en) * 1994-01-31 2006-04-13 The Trustees Of Boston University Polyclonal antibody libraries
AT243745T (en) 1994-01-31 2003-07-15 Univ Boston Libraries of polyclonal antibodies
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6696251B1 (en) * 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
US6261804B1 (en) * 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US8207093B2 (en) 1997-01-21 2012-06-26 The General Hospital Corporation Selection of proteins using RNA-protein fusions
EP0971946B1 (en) 1997-01-21 2006-07-05 The General Hospital Corporation Selection of proteins using rna-protein fusions
US6555310B1 (en) 1997-04-04 2003-04-29 Biosite Diagnostics, Inc. Polyclonal libraries
EP0985033A4 (en) * 1997-04-04 2005-07-13 Biosite Inc Polyvalent and polyclonal libraries
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
AU9796698A (en) * 1997-10-09 1999-05-03 Ixsys, Incorporated Method for identifying optimal binding ligands to a receptor
US6100063A (en) * 1998-02-12 2000-08-08 Novo Nordisk A/S Procaryotic cell comprising at least two copies of a gene
EP1093457B8 (en) 1998-03-19 2011-02-02 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
WO1999051773A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
CA2334946A1 (en) 1998-08-17 2000-02-24 Phylos, Inc. Methods for producing nucleic acids lacking 3'-untranslated regions and optimizing cellular rna-protein fusion formation
DE69941193D1 (en) 1998-08-17 2009-09-10 Bristol Myers Squibb Co Identification of compound protein interactions with libraries of coupled protein nucleic acid molecules
DK1137812T3 (en) 1998-12-02 2007-05-21 Adnexus Therapeutics Inc DNA-protein fusions and uses thereof
KR100713953B1 (en) 1999-02-09 2007-05-02 제너럴 하스피톨 코포레이션 Selection of proteins using rna-protein fusions
CA2363779A1 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
EP1161589B1 (en) * 1999-03-16 2003-07-23 Kao Corporation Liquid deodorant
CA2365870C (en) 1999-03-31 2011-06-28 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Typing of human enteroviruses
EP1187626A4 (en) 1999-06-01 2006-07-19 Compound Therapeutics Inc Methods for producing 5'-nucleic acid-protein conjugates
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
US7135287B1 (en) 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
US20070111259A1 (en) * 1999-10-02 2007-05-17 Medarex, Inc. Human antibodies
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7419792B2 (en) 1999-10-08 2008-09-02 Arius Research Inc. Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody
US7252821B2 (en) 1999-10-08 2007-08-07 Arius Research Inc. Cancerous disease modifying antibodies
US7442776B2 (en) 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
US6657048B2 (en) 1999-10-08 2003-12-02 Arius Research, Inc. Individualized anti-cancer antibodies
US7442777B2 (en) 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US6680209B1 (en) * 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
US7022479B2 (en) * 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
DE60118527D1 (en) 2000-01-24 2006-05-18 Compound Therapeutics Inc Sensitive and multiplexed diagnostic tests for protein analysis
EP1366058B1 (en) 2001-02-09 2011-01-26 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
AU5906601A (en) 2000-04-12 2001-10-30 Human Genome Sciences Inc Albumin fusion proteins
US7439330B2 (en) * 2000-05-08 2008-10-21 President And Fellows Of Harvard College Anti-glycated CD59 antibodies and uses thereof
US6835545B2 (en) 2000-05-08 2004-12-28 President And Fellows Of Harvard College Methods, products and treatments for diabetes
AU6206701A (en) * 2000-05-26 2001-12-03 Symphogen As Recombinant or purified polyclonal antibodies for treating allergy
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
EP2431054A3 (en) 2000-06-15 2013-03-06 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
KR20120053525A (en) 2000-06-16 2012-05-25 캠브리지 안티바디 테크놀로지 리미티드 Antibodies that immunospecifically bind to blys
US6638312B2 (en) * 2000-08-04 2003-10-28 Depuy Orthopaedics, Inc. Reinforced small intestinal submucosa (SIS)
GB0022978D0 (en) 2000-09-19 2000-11-01 Oxford Glycosciences Uk Ltd Detection of peptides
DK1360208T3 (en) * 2000-11-08 2008-08-25 Arius Res Inc Method for Preparation of Cytotoxic Anticancer Antibodies
DE60126130T2 (en) * 2000-11-17 2007-10-18 The University Of Rochester In-vitro process for the manufacture and identification of immunoglobulin molecules in eukaryotic cells
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
EP2027874B1 (en) 2000-11-28 2013-10-16 Medimmune, Inc. Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
AU2027502A (en) * 2000-12-08 2002-06-18 Univ Illinois Mutated class II major histocompatibility proteins
PT1355919E (en) 2000-12-12 2011-03-02 Medimmune Llc Molecules with extended half-lives, compositions and uses thereof
US20030104402A1 (en) * 2001-01-23 2003-06-05 University Of Rochester Methods of producing or identifying intrabodies in eukaryotic cells
AU2002250064B2 (en) * 2001-02-13 2008-01-17 University Of Florida Research Foundation, Inc. A bi-directional dual promoter complex with enhanced promoter activity for transgene expression in eukaryotes
EP1377165B1 (en) 2001-03-14 2009-07-01 Myriad Genetics, Inc. Tsg101-gag interaction and use thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
KR20030093316A (en) 2001-04-13 2003-12-06 휴먼 게놈 사이언시즈, 인코포레이티드 Vascular endothelial growth factor 2
CA2446723C (en) 2001-05-25 2014-01-21 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
AU2002332595A1 (en) * 2001-08-22 2003-03-10 Steven Kessler Methods for screening antibody-producing cells on heterogenous antigen substrates
US20060073095A1 (en) * 2001-08-22 2006-04-06 Steven Kessler Methods for screening antibody-producing cells on heterogeneous antigen substrates
AU2002326710A1 (en) * 2001-08-22 2003-04-14 Steven Kessler Methods for screening monoclonal antibodies on heterogeneous antigen substrates
US6696271B2 (en) * 2001-08-23 2004-02-24 The Regents Of The University Of California Frozen tissue microarray technology for analysis of RNA, DNA, and proteins
US20050048566A1 (en) * 2001-08-27 2005-03-03 Delisi Charles Apparatus, composition and method for proteome profiling
US20030186374A1 (en) * 2001-10-01 2003-10-02 Hufton Simon E. Multi-chain eukaryotic display vectors and uses thereof
US20040005709A1 (en) * 2001-10-24 2004-01-08 Hoogenboom Henricus Renerus Jacobus Mattheus Hybridization control of sequence variation
EP1757305A3 (en) * 2001-12-21 2007-03-14 Arius Research, Inc. Individualized anti-cancer antibodies
PT1463751E (en) 2001-12-21 2013-08-26 Human Genome Sciences Inc Albumin fusion proteins
AU2002226211A1 (en) * 2001-12-21 2003-07-15 Arius Research, Inc. Individualized anti-cancer antibodies
US7244592B2 (en) * 2002-03-07 2007-07-17 Dyax Corp. Ligand screening and discovery
CN1186445C (en) * 2002-03-15 2005-01-26 陈志南 Light chain or heavy chain variable region gene of human liver cancer monoclonal antibody HAb18 and its application
GB0207533D0 (en) 2002-04-02 2002-05-08 Oxford Glycosciences Uk Ltd Protein
US7357928B2 (en) 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
US7541150B2 (en) 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
JP2005535572A (en) 2002-04-12 2005-11-24 メディミューン,インコーポレーテッド Recombinant anti-interleukin-9 antibody
US7012100B1 (en) * 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
US7563882B2 (en) 2002-06-10 2009-07-21 University Of Rochester Polynucleotides encoding antibodies that bind to the C35 polypeptide
DE60319259T2 (en) * 2002-06-14 2009-03-05 Dyax Corp., Cambridge Recombination of nucleic acid library members
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
JP4836451B2 (en) 2002-07-18 2011-12-14 メルス ベー ヴェー Recombinant production of antibody mixtures
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
US7425620B2 (en) 2002-08-14 2008-09-16 Scott Koenig FcγRIIB-specific antibodies and methods of use thereof
MXPA05002934A (en) * 2002-09-18 2006-02-24 Univ Pennsylvania Compositions, methods and kits for detection of an antigen on a cell and in a biological mixture.
SI2301965T1 (en) 2002-10-16 2015-07-31 Purdue Pharma L.P. Antibodies that bind cell-associated CA 125/O722P and methods of use thereof
US20050147962A1 (en) * 2002-11-19 2005-07-07 Wagstrom Christopher R. Display of dimeric proteins on phage
US20060275766A1 (en) * 2003-01-07 2006-12-07 Haurum John S Method for manufacturing recombinant polyclonal proteins
CN100383244C (en) * 2003-01-07 2008-04-23 西福根有限公司 Method for manufacturing recombinant polyclonal proteins
JP4589914B2 (en) * 2003-01-07 2010-12-01 シムフォゲン・アクティーゼルスカブSymphogen A/S Method for producing recombinant polyclonal protein
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
ES2347959T3 (en) 2003-02-20 2010-11-26 Seattle Genetics, Inc. Anti-cd70-farmaco antibodies conjugates and their use for cancer treatment.
RS54160B1 (en) 2003-03-19 2015-12-31 Biogen Idec Ma Inc. Nogo receptor binding protein
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
EP1625166B1 (en) 2003-05-12 2015-04-08 Helion Biotech ApS Antibodies to masp-2
CA2527694C (en) 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs
US7393534B2 (en) 2003-07-15 2008-07-01 Barros Research Institute Compositions and methods for immunotherapy of cancer and infectious diseases
AU2004263896A1 (en) 2003-08-08 2005-02-17 Genenews Inc. Osteoarthritis biomarkers and uses thereof
CA2536238C (en) 2003-08-18 2015-04-07 Medimmune, Inc. Humanization of antibodies
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
US20050164238A1 (en) * 2003-09-29 2005-07-28 Biosite, Inc. Methods and compositions for the diagnosis of sepsis
US20050148029A1 (en) * 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
IL158287D0 (en) 2003-10-07 2004-05-12 Yeda Res & Dev Antibodies to nik, their preparation and use
ES2554645T3 (en) 2003-11-21 2015-12-22 Ucb Biopharma Sprl Method for the treatment of multiple sclerosis by inhibition of IL-17 activity
WO2005063817A2 (en) * 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
NZ548828A (en) 2004-01-20 2009-07-31 Merus B V Mixtures of binding proteins
ES2567634T3 (en) 2004-02-09 2016-04-25 Human Genome Sciences, Inc. Albumin fusion proteins
US7973134B2 (en) 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
US7935790B2 (en) 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
WO2005097184A2 (en) 2004-03-26 2005-10-20 Human Genome Sciences, Inc. Antibodies against nogo receptor
US20050260710A1 (en) * 2004-03-31 2005-11-24 Sekisui Chemical Co. Ltd. Methods for producing recombinant polyclonal immunoglobulins
EP1707628B1 (en) * 2005-03-30 2009-11-11 Sekisui Chemical Co., Ltd. Methods for producing recombinant polyclonal immunoglobulins
CA2578670C (en) 2004-04-15 2017-03-07 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
CA2562764A1 (en) 2004-04-23 2005-11-03 Richard Kroczek Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
US8486893B2 (en) 2004-06-24 2013-07-16 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
MX2007000644A (en) * 2004-07-20 2007-03-28 Symphogen As Anti-rhesus d recombinant polyclonal antibody and methods of manufacture.
EP1787126B1 (en) * 2004-07-20 2009-09-23 Symphogen A/S A procedure for characterization of a polyclonal cell line
WO2006017673A2 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
US20060068421A1 (en) * 2004-08-05 2006-03-30 Biosite, Inc. Compositions and methods for phage display of polypeptides
WO2006034292A2 (en) 2004-09-21 2006-03-30 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2006047417A2 (en) 2004-10-21 2006-05-04 University Of Florida Research Foundation, Inc. Detection of cannabinoid receptor biomarkers and uses thereof
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
US8013116B2 (en) 2004-11-29 2011-09-06 Universite Henri-Poincare-Nancy I Therapeutic peptides and method
US7807789B2 (en) 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
US7833725B2 (en) 2005-01-06 2010-11-16 President And Fellows Of Harvard College Mass spectrometric methods and products
JP5265923B2 (en) 2005-02-07 2013-08-14 ジーンニュース インコーポレーテッド Biomarkers for mild osteoarthritis and uses thereof
EP2548575A1 (en) 2005-02-15 2013-01-23 Duke University Anti-CD19 antibodies that mediate ADCC for use in treating autoimmune diseases
JP2008531730A (en) 2005-03-04 2008-08-14 キュアーディーエム、インク. Methods and pharmaceutical compositions for treating type I diabetes mellitus and other conditions
AU2006227377B2 (en) 2005-03-18 2013-01-31 Medimmune, Llc Framework-shuffling of antibodies
US7618809B2 (en) 2005-03-23 2009-11-17 Gebing Ronald A Microarrayer with coaxial multiple punches
GB0506912D0 (en) 2005-04-05 2005-05-11 Celltech R&D Ltd Biological products
AU2006236439B2 (en) 2005-04-15 2012-05-03 Macrogenics, Inc. Covalent diabodies and uses thereof
AU2006244445B2 (en) 2005-05-05 2013-04-18 Duke University Anti-CD19 antibody therapy for autoimmune disease
JP2008545712A (en) 2005-05-25 2008-12-18 キュアーディーエム、インク. Peptides, derivatives and analogs thereof, and methods of using them
US20070110757A1 (en) 2005-06-23 2007-05-17 Ziping Wei Antibody formulations having optimized aggregation and fragmentation profiles
ES2434470T3 (en) 2005-07-08 2013-12-16 Biogen Idec Ma Inc. SP35 antibodies and their uses
US20080307549A1 (en) 2005-08-03 2008-12-11 Adelaide Research & Innovation Pty Ltd. Polysaccharide Synthases
EP2500353A3 (en) 2005-08-19 2012-10-10 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
SG2014010029A (en) 2005-08-19 2014-08-28 Abbott Lab Dual variable domain immunoglobin and uses thereof
WO2007027906A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
US20100151495A9 (en) * 2005-08-31 2010-06-17 Cell Signaling Technolgy, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US20090258442A1 (en) * 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
CA2620362A1 (en) 2005-09-14 2007-03-22 Ucb Pharma S.A. Comb polymers
ES2542501T3 (en) 2005-09-30 2015-08-06 Abbvie Deutschland Gmbh & Co Kg Protein binding domains of the protein family of repulsive targeting molecules (RGM) and functional fragments thereof, as well as their use
CN102260742A (en) 2005-10-21 2011-11-30 基因信息股份有限公司 Method and apparatus for making products of the biomarkers associated with a disease level for
WO2007056161A1 (en) 2005-11-04 2007-05-18 Biogen Idec Ma Inc. Methods for promoting neurite outgrowth and survival of dopaminergic neurons
CN101500592A (en) 2005-11-07 2009-08-05 斯克利普斯研究院 Compositions and methods for controlling tissue factor signaling specificity
ES2409835T3 (en) 2005-11-28 2013-06-28 Zymogenetics, Inc. IL-21 Antagonists
AU2006320392B2 (en) 2005-11-30 2013-01-17 AbbVie Deutschland GmbH & Co. KG Monoclonal antibodies against amyloid beta protein and uses thereof
ES2524984T3 (en) 2005-11-30 2014-12-16 Abbvie Inc. Anti-globulomer antibodies to? Antigen-binding portions thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies, compositions comprising said antibodies, uses of said antibodies, and methods for using said antibodies
AU2006320479B2 (en) 2005-12-02 2012-11-08 Biogen Ma Inc. Treatment of conditions involving demyelination
JP5183484B2 (en) 2005-12-09 2013-04-17 ユセベ ファルマ ソシエテ アノニム Antibody molecule having specificity for human IL-6
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
WO2007089601A2 (en) 2006-01-27 2007-08-09 Biogen Idec Ma Inc. Nogo receptor antagonists
EP1999148B8 (en) 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US7504106B2 (en) * 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
JP2009530299A (en) 2006-03-15 2009-08-27 アレクシオン ファーマシューティカルズ, インコーポレイテッド Treatment of patients with paroxysmal nocturnal hemoglobinuria with inhibitors of complement
WO2007127335A2 (en) * 2006-04-27 2007-11-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in atm and atr kinase signaling pathways
EP3118221B1 (en) 2007-02-26 2019-08-21 Oxford BioTherapeutics Ltd Proteins
GB0611116D0 (en) 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
SG10201504662WA (en) 2006-06-14 2015-07-30 Macrogenics Inc Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
ES2599319T3 (en) 2006-06-26 2017-02-01 Macrogenics, Inc. Fc RIIB specific antibodies and their methods of use
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
AU2007269714A1 (en) 2006-07-03 2008-01-10 Charles David Adair Composition for modulating the expression of cell adhesion molecules
CN103289980A (en) 2006-07-05 2013-09-11 催化剂生物科学公司 Protease screening methods and proteases indentified thererby
EP2145902A3 (en) 2007-04-19 2010-09-29 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
NZ574215A (en) 2006-07-18 2012-07-27 Sanofi Aventis Antagonist antibody against epha2 for the treatment of cancer
US7939636B2 (en) 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
CA2661782C (en) 2006-08-28 2019-04-16 La Jolla Institute For Allergy And Immunology Antagonistic human light-specific human monoclonal antibodies
AU2007293013B2 (en) 2006-09-05 2013-06-27 Alexion Pharmaceuticals, Inc. Method and compositions for the treatment of antibody mediated neuropathies
AU2007351514B2 (en) 2006-09-08 2013-02-21 Abbvie Inc. Interleukin -13 binding proteins
WO2008048545A2 (en) 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EA200900568A1 (en) * 2006-10-20 2010-04-30 Аризона Борд Оф Риджентс Фор Энд Он Бихаф Оф Аризона Стейт Юниверсити Modified cyanobacteria
RU2009121641A (en) 2006-11-09 2010-12-20 Айрм Ллк (Bm) Agonistic antibodies to TrkB and their application
US8785400B2 (en) 2006-11-22 2014-07-22 Curedm Group Holdings, Llc Methods and compositions relating to islet cell neogenesis
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
SI2099823T1 (en) 2006-12-01 2015-01-30 Seattle Genetics, Inc. Variant target binding agents and uses thereof
CN101678100A (en) 2006-12-06 2010-03-24 米迪缪尼有限公司 methods of treating systemic lupus erythematosus
DK2068887T3 (en) 2007-01-09 2014-05-19 Biogen Idec Inc SP35 antibodies and their applications
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
WO2008101184A2 (en) 2007-02-16 2008-08-21 The Board Of Trustees Of Southern Illinois University Arl-1 specific antibodies
US8685666B2 (en) 2007-02-16 2014-04-01 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies and uses thereof
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
ES2369946T3 (en) 2007-03-01 2011-12-09 Symphogen A/S Procedure for cloning analog antibodies.
EP1972639A3 (en) 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
WO2008118356A2 (en) 2007-03-22 2008-10-02 Biogen Idec Ma Inc. Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
US20090068684A1 (en) * 2007-03-26 2009-03-12 Cell Signaling Technology, Inc. Serine and threoninephosphorylation sites
US20080238709A1 (en) * 2007-03-28 2008-10-02 Faramarz Vaziri One-way communication apparatus with dynamic key generation
AU2008232903B9 (en) 2007-03-30 2013-09-05 Medimmune Llc Antibodies with decreased deamidation profiles
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP1983003A3 (en) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP2164868B1 (en) 2007-05-04 2015-03-25 Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA Engineered rabbit antibody variable domains and uses thereof
EP2737907A3 (en) 2007-05-07 2014-11-05 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CA2685222C (en) 2007-05-14 2017-12-19 Medimmune, Llc Methods of reducing eosinophil levels
MX2009013269A (en) 2007-06-05 2010-04-21 Univ Yale Inhibitors of receptor tyrosine kinases and methods of use thereof.
WO2008157379A2 (en) 2007-06-21 2008-12-24 Macrogenics, Inc. Covalent diabodies and uses thereof
EA201000399A1 (en) 2007-08-30 2011-02-28 Кьюрдм, Инк. Compositions and methods of using pro-island peptides and their analogues
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
CA2700714C (en) 2007-09-26 2018-09-11 Ucb Pharma S.A. Dual specificity antibody fusions
US20090099340A1 (en) * 2007-10-12 2009-04-16 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
WO2009051846A2 (en) 2007-10-18 2009-04-23 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
NZ585064A (en) 2007-11-05 2012-08-31 Medimmune Llc Methods of treating scleroderma
CA2705486C (en) 2007-11-19 2019-04-02 Celera Corporation Lung cancer markers and uses thereof
EP2062920A3 (en) 2007-11-21 2009-06-17 Peter Hornbeck Protein phosphorylation by basophilic serine/threonine kinases in insulin signalling pathways
WO2009070642A1 (en) 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
GB0800277D0 (en) 2008-01-08 2008-02-13 Imagination Tech Ltd Video motion compensation
EP2245156A4 (en) 2008-01-11 2011-02-02 Gene Techno Science Co Ltd Humanized anti- 9 integrin antibodies and the uses thereof
AU2009205995B2 (en) 2008-01-18 2014-04-03 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
US8653020B2 (en) * 2008-01-25 2014-02-18 Aarhus Universitet Selective exosite inhibition of PAPP-A activity against IGFBP-4
PL2250279T3 (en) 2008-02-08 2016-11-30 Anti-ifnar1 antibodies with reduced fc ligand affinity
JP6014706B2 (en) * 2008-02-14 2016-10-25 株式会社イーベック Monoclonal antibody binding to hGM-CSF and pharmaceutical composition comprising said antibody
US20090220991A1 (en) * 2008-02-29 2009-09-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US20110020368A1 (en) 2008-03-25 2011-01-27 Nancy Hynes Treating cancer by down-regulating frizzled-4 and/or frizzled-1
CA2720365C (en) 2008-04-02 2019-01-15 Macrogenics, Inc. Bcr-complex-specific antibodies and methods of using same
EP2247304B1 (en) 2008-04-02 2016-05-25 MacroGenics, Inc. Her2/neu-specific antibodies and methods of using same
WO2009126306A2 (en) 2008-04-10 2009-10-15 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
JP5752592B2 (en) 2008-04-11 2015-07-22 シアトル ジェネティックス, インコーポレイテッド Detection and treatment of pancreatic cancer, ovarian cancer, and other cancers
WO2009129814A1 (en) * 2008-04-23 2009-10-29 Symphogen A/S Methods for manufacturing a polyclonal protein
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
KR101746861B1 (en) 2008-04-24 2017-06-14 가부시키가이샤 진 테크노 사이언스 Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof
MX2010011955A (en) 2008-04-29 2011-01-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof.
CA2723219A1 (en) 2008-05-09 2009-11-12 Abbott Gmbh & Co. Kg Antibodies to receptor of advanced glycation end products (rage) and uses thereof
EP2599793A1 (en) 2008-05-29 2013-06-05 Nuclea Biotechnologies, Inc. Anti-phospho-akt antibodies
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
KR20110016959A (en) 2008-06-03 2011-02-18 아보트 러보러터리즈 Dual variable domain immunoglobulins and uses thereof
WO2010033279A2 (en) 2008-06-04 2010-03-25 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
EP2732823B1 (en) 2008-06-25 2019-08-07 H. Lundbeck A/S Modulation of the TrpV : Vps10p-domain receptor system for the treatment of pain
CN104829718A (en) 2008-07-08 2015-08-12 艾伯维公司 Prostaglandin E2 binding proteins and uses thereof
MX2010014574A (en) 2008-07-08 2011-04-27 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof.
NZ590605A (en) 2008-07-09 2012-11-30 Biogen Idec Inc Compositions comprising antibodies to lingo or fragments thereof
US8148088B2 (en) 2008-07-18 2012-04-03 Abgent Regulation of autophagy pathway phosphorylation and uses thereof
WO2010033237A2 (en) * 2008-09-22 2010-03-25 Calmune Corporation Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules
AU2009293640A1 (en) * 2008-09-22 2010-03-25 Calmune Corporation Methods and vectors for display of 2G12 -derived domain exchanged antibodies
EP3351628A1 (en) 2008-10-24 2018-07-25 The Government of The United States of America as represented by The Secretary, Department of Health and Human Services Human ebola virus species and compositions and methods thereof
WO2010054289A1 (en) * 2008-11-10 2010-05-14 Kids Ii, Inc. Electromagnetic children's bouncer
ES2719496T3 (en) 2008-11-12 2019-07-10 Medimmune Llc Antibody formulation
WO2010065437A1 (en) 2008-12-03 2010-06-10 Research Development Foundation Modulation of olfml-3 mediated angiogenesis
HUE043084T2 (en) 2008-12-19 2019-08-28 Macrogenics Inc Covalent diabodies and uses thereof
CN105641694A (en) 2008-12-19 2016-06-08 H.隆德贝克有限公司 Modulation Of The VPS10p-Domain Receptor Family For The Treatment Of Mental And Behavioural Disorders
JP2012514458A (en) 2008-12-31 2012-06-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド Anti-lymphotoxin antibody
GB0900425D0 (en) 2009-01-12 2009-02-11 Ucb Pharma Sa Biological products
WO2010082134A1 (en) 2009-01-14 2010-07-22 Iq Therapeutics Bv Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
US20130122052A1 (en) 2009-01-20 2013-05-16 Homayoun H. Zadeh Antibody mediated osseous regeneration
EP2389394A2 (en) 2009-01-21 2011-11-30 Oxford Biotherapeutics Ltd. Pta089 protein
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
AU2010213578B2 (en) 2009-02-12 2015-01-29 Cell Signaling Technology, Inc. Mutant ROS expression in human cancer
WO2010093993A2 (en) 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
EA201171060A1 (en) 2009-02-17 2012-07-30 Юсб Фарма С.А. Molecules of antibodies with peculiarity of the human oh40
PE20121094A1 (en) 2009-03-05 2012-09-13 Abbvie Inc Binding proteins IL-17
EP2405920A1 (en) 2009-03-06 2012-01-18 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Novel therapy for anxiety
US8735552B2 (en) 2009-03-10 2014-05-27 Gene Techno Science Co., Ltd. Generation, expression and characterization of the humanized K33N monoclonal antibody
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
WO2010112034A2 (en) 2009-04-02 2010-10-07 Aarhus Universitet Compositions and methods for treatment and diagnosis of synucleinopathies
EP2241323A1 (en) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W and brain cancers
PE20121397A1 (en) 2009-04-20 2012-10-23 Oxford Biotherapeutics Ltd antibodies specific for cadherin-17
RU2012101999A (en) 2009-06-22 2013-07-27 МЕДИММЬЮН, ЭлЭлСи Fc RECOMBINED SITES FOR SITE-SPECIFIC CONJUGATION
CA2770737A1 (en) 2009-08-13 2011-02-17 Crucell Holland B.V. Antibodies against human respiratory syncytial virus (rsv) and methods of use
EP2292266A1 (en) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Treating cancer by modulating copine III
BR112012004546A2 (en) 2009-08-29 2016-11-29 Abbott Lab "dll4-ligand protein therapy"
EP2473524A4 (en) 2009-09-01 2013-05-22 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
EP2480573A1 (en) 2009-09-22 2012-08-01 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mex-3
TW201116297A (en) 2009-10-02 2011-05-16 Sanofi Aventis Antibodies that specifically bind to the EphA2 receptor
EP2470569A1 (en) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Antibodies against epha10
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
AR078651A1 (en) 2009-10-15 2011-11-23 Abbott Lab Immunoglobulins Dual variable domain and uses thereof
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
CN102781963B (en) 2009-10-27 2018-02-16 Ucb医药有限公司 Functionalized modification NAv1.7 antibody
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab Immunoglobulins Dual variable domain and uses thereof
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
US8420083B2 (en) 2009-10-31 2013-04-16 Abbvie Inc. Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
EP2496605A1 (en) 2009-11-02 2012-09-12 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
US9588121B2 (en) 2009-11-06 2017-03-07 Go Therapeutics, Inc. Method for early detection of cancer
WO2011058087A1 (en) 2009-11-11 2011-05-19 Gentian As Immunoassay for assessing related analytes of different origin
CN108707584A (en) 2009-11-17 2018-10-26 Musc研究发展基金会 For the human monoclonal antibodies of people's paranuclein
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
CA2780069C (en) 2009-12-08 2018-07-17 Abbott Gmbh & Co. Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
ES2603559T3 (en) 2010-02-08 2017-02-28 Regeneron Pharmaceuticals, Inc. Common mouse light chain
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
KR101853278B1 (en) 2010-03-02 2018-05-02 애브비 인코포레이티드 Therapeutic dll4 binding proteins
EP2542578A1 (en) 2010-03-05 2013-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Smoc1, tenascin-c and brain cancers
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
WO2011117653A1 (en) 2010-03-25 2011-09-29 Ucb Pharma S.A. Disulfide stabilized dvd-lg molecules
CA2796339A1 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
EP2561076A1 (en) 2010-04-19 2013-02-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulating xrn1
EP2380909A1 (en) 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PTK-7 protein involved in breast cancer
CA2797856C (en) 2010-04-30 2018-09-18 Alexion Pharmaceuticals, Inc. Anti-c5a antibodies and methods for using the antibodies
UY33386A (en) 2010-05-14 2011-12-30 Abbott Laboratoires Binding proteins yl-1
WO2011141823A2 (en) 2010-05-14 2011-11-17 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
US20130089538A1 (en) 2010-06-10 2013-04-11 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh Treating cancer by modulating mammalian sterile 20-like kinase 3
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (en) 2010-07-09 2012-01-31 Abbott Lab Immunoglobulins Dual variable domain and uses thereof
EP2591000B1 (en) 2010-07-09 2017-05-17 Janssen Vaccines & Prevention B.V. Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
MX339622B (en) 2010-08-02 2016-06-02 Macrogenics Inc Covalent diabodies and uses thereof.
BR112013002578A2 (en) 2010-08-03 2019-05-14 Abbvie Inc immunoglobulins dual variable domain and uses the same
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins
JP6121903B2 (en) 2010-08-19 2017-04-26 ゾエティス・ベルジャム・エス・アー Anti-NGF antibodies and uses thereof
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
US9068006B2 (en) 2010-08-25 2015-06-30 President And Fellows Of Harvard College Glycated CD59 peptides, their preparation, and uses thereof
BR112013004581A2 (en) 2010-08-26 2017-06-27 Abbvie Inc dual variable domain immunoglobulins and their uses
WO2012032143A1 (en) 2010-09-10 2012-03-15 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Phosphorylated twist1 and metastasis
US20140093506A1 (en) 2010-11-15 2014-04-03 Marc Buehler Anti-fungal-agents
US20120275996A1 (en) 2010-12-21 2012-11-01 Abbott Laboratories IL-1 Binding Proteins
PE20141060A1 (en) 2010-12-21 2014-09-26 Abbvie Inc Immunoglobulins Dual variable domain bispecific IL-1 alpha and beta and their use
KR101941514B1 (en) 2010-12-22 2019-01-23 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 Modified antibody with improved half-life
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
CA2823812C (en) 2011-01-14 2017-02-14 Ucb Pharma S.A. Antibody molecules which bind il-17a and il-17f
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
RS57324B1 (en) 2011-04-20 2018-08-31 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
NZ618016A (en) 2011-05-21 2015-05-29 Macrogenics Inc Deimmunized serum-binding domains and their use for extending serum half-life
EP3446714A1 (en) 2011-06-02 2019-02-27 University of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles
EP2717911A1 (en) 2011-06-06 2014-04-16 Novartis Forschungsstiftung, Zweigniederlassung Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
JP6058645B2 (en) 2011-06-10 2017-01-11 メディミューン,エルエルシー Anti-Pseudomonas Psl binding molecules and uses thereof
SI2726094T1 (en) 2011-06-28 2017-04-26 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
MX347424B (en) 2011-06-28 2017-04-26 Oxford Biotherapeutics Ltd Antibodies to adp-ribosyl cyclase 2.
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
US8663637B2 (en) 2011-08-05 2014-03-04 Research Development Foundation Methods and compositions for modulation of Olfml3 mediated angiogenesis
US10130081B2 (en) 2011-08-05 2018-11-20 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice
AU2012296613B2 (en) 2011-08-15 2016-05-12 Amplimmune, Inc. Anti-B7-H4 antibodies and their uses
EP2753697A1 (en) 2011-09-05 2014-07-16 ETH Zürich Biosynthetic gene cluster for the production of peptide/protein analogues
US9447192B2 (en) 2011-09-09 2016-09-20 Medimmune Limited Anti-Siglec-15 antibodies and uses thereof
SG11201401791WA (en) 2011-10-24 2014-08-28 Abbvie Inc Immunobinders directed against sclerostin
CA2853951A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Antibodies and methods of treating cancer
EP2773664A1 (en) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49 antibodies
WO2013067060A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
EP2773373B1 (en) 2011-11-01 2018-08-22 Bionomics, Inc. Methods of blocking cancer stem cell growth
WO2013068432A1 (en) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Early diagnostic of neurodegenerative diseases
WO2013068431A1 (en) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
EA201400568A1 (en) 2011-11-11 2014-12-30 Юсб Фарма С.А. Albumins connecting antibodies and their connecting fragments
MX357708B (en) 2011-12-14 2018-07-20 Abbvie Deutschland Composition and method for the diagnosis and treatment of iron-related disorders.
WO2013090633A2 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
ES2721882T3 (en) 2011-12-23 2019-08-06 Pfizer Constant regions of genetically engineered antibody for site-specific conjugation and procedures and uses thereof
BR112014015851A2 (en) 2011-12-30 2019-09-24 Abbvie Inc double specific binding proteins directed against il-13 and / or il-17
WO2013102825A1 (en) 2012-01-02 2013-07-11 Novartis Ag Cdcp1 and breast cancer
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
BR112014018592A2 (en) 2012-01-27 2017-07-04 Abbvie Deutschland composition and method for the diagnosis and treatment of diseases associated with neuronal degeneration
CN104203977A (en) 2012-02-15 2014-12-10 诺和诺德A/S(股份有限公司) Antibodies that bind peptidoglycan recognition protein 1
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
CN108103069A (en) 2012-02-15 2018-06-01 诺和诺德股份有限公司 With reference to and block myeloid cell express triggering receptor -1 (TREM-1) antibody
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
US9421250B2 (en) 2012-03-23 2016-08-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pathogenic phlebovirus isolates and compositions and methods of use
WO2013144240A1 (en) 2012-03-29 2013-10-03 Friedrich Miescher Institute For Biomedical Research Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
WO2013143026A1 (en) * 2012-03-31 2013-10-03 Abmart (Shanghai) Co., Ltd Peptide and antibody libraries and uses thereof
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
EP2838998B1 (en) 2012-04-18 2017-10-11 Cell Signaling Technology, Inc. Egfr and ros1 in cancer
SG11201406770WA (en) 2012-04-20 2014-11-27 Merus B V Methods and means for the production of ig-like molecules
KR20150020190A (en) 2012-05-14 2015-02-25 바이오겐 아이덱 엠에이 인코포레이티드 Lingo-2 antagonists for treatment of conditions involving motor neurons
US9512223B2 (en) 2012-05-15 2016-12-06 Morphotek, Inc. Methods for treatment of gastric cancer
JP2015521461A (en) 2012-06-06 2015-07-30 ゾエティス・エルエルシー Caninized anti-NGF antibody and method thereof
WO2014001557A1 (en) 2012-06-28 2014-01-03 Ucb Pharma S.A. A method for identifying compounds of therapeutic interest
WO2014001482A1 (en) 2012-06-29 2014-01-03 Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research Treating diseases by modulating a specific isoform of mkl1
EP2870242A1 (en) 2012-07-05 2015-05-13 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
US20150224190A1 (en) 2012-07-06 2015-08-13 Mohamed Bentires-Alj Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
AR091755A1 (en) 2012-07-12 2015-02-25 Abbvie Inc Binding proteins yl-1
CN102851338A (en) 2012-07-25 2013-01-02 苏州康宁杰瑞生物科技有限公司 Method for preparing homodimer protein mixture by using charge repulsive interaction
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
US9365641B2 (en) 2012-10-01 2016-06-14 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
BR112015008118A2 (en) 2012-10-12 2017-12-05 Brigham & Womens Hospital Inc immune response booster
CA2888345A1 (en) 2012-10-24 2014-05-01 Research Development Foundation Jam-c antibodies and methods for treatment of cancer
KR20190107184A (en) 2012-11-01 2019-09-18 애브비 인코포레이티드 Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
US9550986B2 (en) 2012-12-21 2017-01-24 Abbvie Inc. High-throughput antibody humanization
CA2896091C (en) 2012-12-21 2018-06-19 Amplimmune, Inc. Anti-h7cr antibodies
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
AU2013202668B2 (en) 2012-12-24 2014-12-18 Adelaide Research & Innovation Pty Ltd Inhibition of cancer growth and metastasis
EP2970947A4 (en) 2013-03-14 2016-10-12 Abbott Lab Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
EP2971046A4 (en) 2013-03-14 2016-11-02 Abbott Lab Hcv core lipid binding domain monoclonal antibodies
MX362075B (en) 2013-03-14 2019-01-07 Abbott Lab Hcv antigen-antibody combination assay and methods and compositions for use therein.
AU2014228172B2 (en) 2013-03-15 2018-12-06 Abbvie Deutschland Gmbh & Co.Kg Anti-EGFR antibody drug conjugate formulations
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
JP2016519070A (en) 2013-03-15 2016-06-30 アッヴィ・インコーポレイテッド Purification of antibody-drug conjugate (ADC)
EP2970459A2 (en) 2013-03-15 2016-01-20 AbbVie Inc. Dual specific binding proteins directed against il-1beta and il-17
SG11201508681QA (en) 2013-05-06 2015-11-27 Scholar Rock Inc Compositions and methods for growth factor modulation
SG10201709715RA (en) 2013-05-24 2017-12-28 Medimmune Llc Anti-b7-h5 antibodies and their uses
JP2016527877A (en) 2013-06-06 2016-09-15 アイジェニカ バイオセラピューティクス インコーポレイテッド Anti-C10orf54 antibody and method of use thereof
WO2014197885A2 (en) 2013-06-07 2014-12-11 Duke University Inhibitors of complement factor h
EP3030902B1 (en) 2013-08-07 2019-09-25 Friedrich Miescher Institute for Biomedical Research New screening method for the treatment friedreich's ataxia
WO2015053871A2 (en) 2013-08-26 2015-04-16 MabVax Therapeutics, Inc. NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa
CN108064169A (en) 2015-03-03 2018-05-22 科马布有限公司 Antibody, purposes and method
US9738702B2 (en) 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
JP2017512479A (en) 2014-04-04 2017-05-25 バイオノミクス インコーポレイテッド Humanized antibody that binds to LGR5
CA2949998A1 (en) 2014-05-28 2015-12-03 Agenus Inc. Anti-gitr antibodies and methods of use thereof
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
AU2015271685A1 (en) 2014-06-04 2017-02-02 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside GD2
US20170137824A1 (en) 2014-06-13 2017-05-18 Indranil BANERJEE New treatment against influenza virus
US10308935B2 (en) 2014-06-23 2019-06-04 Friedrich Miescher Institute For Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small RNAS
EP3164129A1 (en) 2014-07-01 2017-05-10 Friedrich Miescher Institute for Biomedical Research Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
TN2017000008A1 (en) 2014-07-17 2018-07-04 Novo Nordisk As Site directed mutagenesis of trem-1 antibodies for decreasing viscosity.
EP3197557A1 (en) 2014-09-24 2017-08-02 Friedrich Miescher Institute for Biomedical Research Lats and breast cancer
US20170304460A1 (en) 2014-10-01 2017-10-26 Medimmune, Llc Method of conjugating a polypeptide
CA2963166A1 (en) 2014-10-01 2016-04-07 Medimmune Limited Antibodies to ticagrelor and methods of use
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
MX2017009038A (en) 2015-01-08 2017-10-25 Biogen Ma Inc Lingo-1 antagonists and uses for treatment of demyelinating disorders.
JP2018520993A (en) 2015-05-07 2018-08-02 アジェナス インコーポレイテッド Anti-OX40 antibody and method of use thereof
CN107660152A (en) 2015-05-27 2018-02-02 Ucb生物制药私人有限公司 Method for treating the nervous system disease
JP2018521638A (en) 2015-05-29 2018-08-09 アジェナス インコーポレイテッド Anti-CTLA-4 antibody and method of use thereof
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
AU2016317915A1 (en) 2015-09-01 2018-03-01 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
CN109310744A (en) 2015-09-23 2019-02-05 赛通免疫有限责任公司 FLT3 for immunization therapy orients CAR cell
EP3368566A1 (en) 2015-10-28 2018-09-05 Friedrich Miescher Institute for Biomedical Research Tenascin-w and biliary tract cancers
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201602413D0 (en) 2016-02-10 2016-03-23 Nascient Ltd Method
JP2019513147A (en) 2016-03-29 2019-05-23 エスティーキューブ,インコーポレイテッド Dual function antibody specific for glycosylated PD-L1 and method of using the same
KR20190021224A (en) 2016-05-27 2019-03-05 아게누스 인코포레이티드 Anti-TIM-3 antibodies and methods of use thereof
EP3481864A1 (en) 2016-07-08 2019-05-15 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
CN109715666A (en) 2016-07-20 2019-05-03 斯特库比股份有限公司 The combined therapy of cancer treatment method and the antibody using combination glycosylation PD-L1
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
CA3036717A1 (en) 2016-10-03 2018-04-12 Abbott Laboratories Improved methods of assessing gfap status in patient samples
AU2017343621A1 (en) 2016-10-11 2019-04-11 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
CN110300600A (en) 2016-11-02 2019-10-01 伊缪诺金公司 Utilize the combined therapy of antibody-drug conjugates and PARP inhibitor
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
AU2017373945A1 (en) 2016-12-07 2019-06-20 Agenus Inc. Antibodies and methods of use thereof
AU2017373944A1 (en) 2016-12-07 2019-06-20 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
WO2018175942A1 (en) 2017-03-23 2018-09-27 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
TW201841942A (en) 2017-04-13 2018-12-01 美商艾吉納斯公司 Anti-CD137 antibodies and methods of use thereof
CA3053409A1 (en) 2017-04-15 2018-10-18 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
AU2018255938A1 (en) 2017-04-21 2019-10-31 Staten Biotechnology B.V. Anti-ApoC3 antibodies and methods of use thereof
CA3053410A1 (en) 2017-04-28 2018-11-01 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
US20180355040A1 (en) 2017-05-01 2018-12-13 Agenus Inc. Anti-tigit antibodies and methods of use thereof
TW201900191A (en) 2017-05-12 2019-01-01 美國西奈山伊坎醫學院 Newcastle disease virus and its use
AU2018272054A1 (en) 2017-05-25 2019-09-26 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
CA3059607A1 (en) 2017-05-30 2018-12-06 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i
WO2018222689A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
WO2018222685A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
WO2018226671A1 (en) 2017-06-06 2018-12-13 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
US20190033327A1 (en) 2017-07-03 2019-01-31 Abbott Laboratories Methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
WO2019036605A2 (en) 2017-08-17 2019-02-21 Massachusetts Institute Of Technology Multiple specificity binders of cxc chemokines and uses thereof
WO2019040780A1 (en) 2017-08-25 2019-02-28 Five Prime Therapeutics Inc. B7-h4 antibodies and methods of use thereof
US20190111164A1 (en) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh Human antibodies to tn antigen
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
WO2019087115A1 (en) 2017-10-31 2019-05-09 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
TW201922294A (en) 2017-10-31 2019-06-16 美商伊繆諾金公司 Combination treatment with antibody-drug conjugates and cytarabine
WO2019100052A2 (en) 2017-11-20 2019-05-23 Compass Therapeutics Llc Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019102435A1 (en) 2017-11-27 2019-05-31 Euro-Celtique S.A. Humanized antibodies targeting human tissue factor
US20190242906A1 (en) 2017-12-09 2019-08-08 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
US20190219598A1 (en) 2017-12-09 2019-07-18 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
WO2019169212A1 (en) 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
WO2019200357A1 (en) 2018-04-12 2019-10-17 Surface Oncology, Inc. Biomarker for cd47 targeting therapeutics and uses therefor
WO2019207159A1 (en) 2018-04-27 2019-10-31 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3590766T (en) 1985-03-30 1987-04-23
US6121424A (en) 1991-11-25 2000-09-19 Enzon, Inc. Multivalent antigen-binding proteins
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5126130A (en) * 1986-11-24 1992-06-30 The Childrens Hospital Incorporated Monoclonal antibodies reactive with specific antigenic sites on human cytomegalovirus glycoprotein a
DE3852304D1 (en) * 1987-03-02 1995-01-12 Enzon Lab Inc Organism as a support for "Single Chain Antibody domain (SCAD)".
US5843708A (en) 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
GB8800077D0 (en) 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
EP0368684B2 (en) * 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
CA2016841C (en) * 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
EP1566442B1 (en) * 1990-02-01 2009-11-25 Siemens Healthcare Diagnostics Products GmbH Preparation and use of a human antibody gene bank (human antibody libraries)
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
CA2131151A1 (en) 1992-03-24 1994-09-30 Kevin S. Johnson Methods for producing members of specific binding pairs
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0605522B1 (en) 1991-09-23 1999-06-23 Cambridge Antibody Technology Limited Methods for the production of humanized antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5871974A (en) 1990-09-28 1999-02-16 Ixsys Inc. Surface expression libraries of heteromeric receptors
AU1457992A (en) * 1991-03-01 1992-10-06 Stratagene Pcr generated dicistronic dna molecules for producing antibodies
US5955341A (en) 1991-04-10 1999-09-21 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE69233750D1 (en) * 1991-04-10 2009-01-02 Scripps Research Inst Libraries of heterodimeric receptors using phagemids
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
PT1696031E (en) 1991-12-02 2010-06-25 Medical Res Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
JPH06509316A (en) 1991-07-29 1994-10-20
WO1993003151A1 (en) * 1991-08-10 1993-02-18 Medical Research Council Treatment of cell populations
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
CA2143104C (en) 1992-09-04 2008-04-08 James Paul Ii Light Phagemids coexpressing a surface receptor and a surface heterologous protein
JPH08504091A (en) 1992-09-22 1996-05-07 メディカル・リサーチ・カウンシル Recombinant virus that presents a non-viral polypeptide to the outer surface
AT233814T (en) 1992-09-30 2003-03-15 Scripps Research Inst Human neutralizing monoclonal antibody against the immunodeficiency produced struggling virus in humans
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
ES2156149T3 (en) 1992-12-04 2001-06-16 Medical Res Council Multivalent and multispecific protein union, their manufacture and use.
US5855885A (en) 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
US5679548A (en) 1993-02-02 1997-10-21 The Scripps Research Institute Methods for producing polypeptide metal binding sites and compositions thereof
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0732404A4 (en) * 1993-12-03 1997-07-30 Asahi Chemical Ind Novel expression screening vector
AT243745T (en) 1994-01-31 2003-07-15 Univ Boston Libraries of polyclonal antibodies
EP0932698A4 (en) 1996-03-26 1999-08-25
US5981199A (en) 1996-06-14 1999-11-09 Boehringer Mannheim Corporation Method for measuring antigen concentration
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries

Also Published As

Publication number Publication date
DE69531148T2 (en) 2004-04-29
AU1736495A (en) 1995-08-15
EP1231268A3 (en) 2002-08-21
DE69534347T2 (en) 2006-05-24
DK0744958T3 (en) 2003-10-20
DK1231268T3 (en) 2005-11-21
DE69534347D1 (en) 2005-09-01
EP1231268A2 (en) 2002-08-14
EP0744958B1 (en) 2003-06-25
WO1995020401A1 (en) 1995-08-03
US5789208A (en) 1998-08-04
PT1231268E (en) 2005-11-30
EP0744958A4 (en) 1997-07-30
EP0744958A1 (en) 1996-12-04
DK744958T3 (en)
AT243745T (en) 2003-07-15
ES2247204T3 (en) 2006-03-01
PT744958E (en) 2003-11-28
US6335163B1 (en) 2002-01-01
ES2201097T3 (en) 2004-03-16
EP1231268B1 (en) 2005-07-27
DE69531148D1 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
DK0941121T3 (en) Stable lyophilized pharmaceutical preparations of mono- or polyclonal antibodies
DE69635700D1 (en) New endoglukanase
DE69635315D1 (en) Kodeverteilvielfachzugriffskommunikationssystem
DE69636130D1 (en) Permeatsammelsystem
DK1419802T3 (en) Gelindkapslingsstruktur
DE69638219D1 (en) Teilchentrennverfahren
DE69635184D1 (en) Vielfachkapillarfluoreszenzsensoranordnung
DE69636827D1 (en) Spreizspektrumübertragungsgerät
DE69636741D1 (en) Bleichkatalysatorteilchen
DE69633991D1 (en) Kodemultiplexmehrfachzugriffsbasisstationssender
DE69637079D1 (en) Hochgeschwindigkeitschromatographie
DE69634614D1 (en) Spreizspektrumübertragungsgerät
DE69634097D1 (en) Einfürungsvorrichtung
DE69637794D1 (en) Sprühpistolekörper
DE69638204D1 (en) Magnetic way sensor
DE69636538D1 (en) Antagonist of interleukin-15
DE69635284D1 (en) New substituted napthopyranees
DE69735780D1 (en) Ferromagnetic memory of fip-flop type
DK2025753T3 (en) Expert for screening antibodies
DE69635406D1 (en) Chemokin receptor 88c and its antibodies
DE69634001D1 (en) Beleuchtungssystème
DE69635704D1 (en) Zahnfleischretraktionsvorrichtung
DE69636278D1 (en) Inhibitor of muscle protein removal contained an il-6 receptor antibody
DE69535333D1 (en) Combinatorial synthesis of new materials
DE69636791D1 (en) Derivatives of glycopeptidantibiotics

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1231268

Country of ref document: EP